



2ND D&IOD 2017 The SECOND INTERNATIONAL CONFERENCE " Orphan Drugs. Discoveries and Innovations "

The SECOND INTERNATIONAL CONFERENCE " Orphan Drugs. Discoveries and Innovations " (2nd D&IOD) will take place in Moscow in Russian President Academy of National Economy and Public Administration (RANEPA) on 16-17 February. Meeting in such global level will take place for a first time in Russian Federation and will bring together the leading Russian and foreign developers of orphan drugs, with purpose to present the latest diagnostics, projects and methods of treatment, discussion and the presentation of products and developments, and also exchange of experience and knowledge.

Our start-up experience was done at Mexico City, October 2015, as part of the Mexican Rare Diseases Global Week, organized by ICORD, Geiser Foundation and FEMEXER. The largest companies have taken part in this conference: Genzyme, Shire, BMS, Actelion, Biomarin, CSL, Behring, SOBI, Recordati. Subjects of discussion: international cooperation, creation of networks, financial aid, cooperation of multinational research groups and developers in the sphere of rare (orphan) drugs and rare medical technologies.

2ND D&IOD will invite all Russian and foreign experts and professionals in the field of development of orphan drugs, representatives of the leading pharmaceutical companies, public authorities, non-profit organizations and mass media. Special session will be organized in the main programme of meeting – the "brainstorming session" devoted to discuss about the feasibility of building coalition between the countries of EAEU, Argentina, China, India, Korea, Bulgaria and other countries. Countries willing to intervene and solve the impact of orphan drugs at its national health economies.

Rare diseases and its specific pharmacological treatments, the orphan drugs, are now more visible after years of patient organizations awareness campaigns and negotiations with government's, industries and academia's. Some innovative therapies are already in the market starting to change lives in patients which were hopeless just few years ago. The earliest achievements aroused the interest of many scientists, and small and big pharma companies for research in new pathogenic pathways, enhancing the global knowledge in favor of the understanding of both rare and common diseases. The appearance of an orphan drug market was necessary to sustain the impulses and encourages others to follow in the same direction. Therefore, the "Discoveries and Innovations on Orphan Drugs (D&IOD) meetings were thought by patient organizations in order to take the flame to all the corners of the world, to motivate, learn from and link projects, and to facilitate the technological inputs expediting the orphan drug R&D and its accessibility world-wide.

This second D&IOD will be organized by National Association « Genetics» Russia and GEISER Foundation seeking for expediting the orphan drug availabilities and technological linkage. Indeed, in spite of all the advancements done till now, it is estimated that at the current pace of progress it will demand 4-5 centuries to cover the pending unsatisfied needs. Hence, there is need for more players involved in the field, more networking and cooperation, and of balanced formulas to invest and to finance the available products.

We invite you to become part of the event!

Contacts:

National Association of organizations of patients with rare diseases «Genetics»
191036, Saint-Petersburg, 2 Sovetskaya str., appart. 7, of 401, " Senator "

Tel./fax: [\[812\] 449 96 09](tel:+78124499609) [+7\(921\) 095 38 39](tel:+79210953839)

Email: nacgenetic@raredis.org pomppez@raredis.org

www.nacgenetic.ru